US FDA rejects lung cancer drug from China

Cover art for US FDA rejects lung cancer drug from China

TL;DR: US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma, after clinical trials failed to show statistically significant life extension. US FDA rejects Chinese lung cancer drug after trial shows no life extension. US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma and licensed by Summit Therapeutics, after clinical trials failed to show statistically significant life extension.

Nov 16, 2026

From · · 50s

TL;DR: US FDA rejects lung cancer drug from China

US FDA rejects Chinese lung cancer drug after trial shows no life extension.

US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma, after clinical trials failed to show statistically significant life extension. US FDA rejects Chinese lung cancer drug after trial shows no life extension. US FDA rejected ivonescimab, a lung cancer drug invented by China's Akeso Biopharma and licensed by Summit Therapeutics, after clinical trials failed to show statistically significant life extension.

  • FDA rejection
  • Drug development setback
  • Market impact

Read the story version — the same reporting as a swipeable deck of 3 cards.

Read the original on The Straits Times

More news from China

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on us food and drug administration and related topics.